Show simple item record

dc.contributor.authorSomervaille, Tim C Pen
dc.contributor.authorCleary, Michael Len
dc.date.accessioned2010-08-04T11:47:09Z
dc.date.available2010-08-04T11:47:09Z
dc.date.issued2010-06
dc.identifier.citationGrist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? 2010, 91 (5):735-41 Int J Hematolen
dc.identifier.issn1865-3774
dc.identifier.pmid20454944
dc.identifier.doi10.1007/s12185-010-0579-8
dc.identifier.urihttp://hdl.handle.net/10541/109045
dc.description.abstractMLL fusion oncogenes are pathogenically associated with 5-10% of human acute leukemias. Through multiple interactions with chromatin regulatory factors, they convert a normal hematopoietic hierarchy into a leukemia cell hierarchy sustained at its apex by a population of inappropriately self-renewing myeloid cells termed leukemia stem cells (LSCs). Initiation of the aberrant leukemia cell hierarchy is associated with an abnormal epigenetic state at Hoxa and Meis1 loci, with concomitant high level Hoxa and Meis1 expression. This introduces at the level of the myeloblast, or thereabouts, a finite probability of self-renewal division where none previously existed. In contrast, differentiation-mediated exit of LSCs from the self-renewing compartment of the leukemia clone depends on the prevailing levels of the transcription factor Myb, which functions as part of an LSC maintenance program influenced, but not directly controlled, by Hoxa and Meis1. Critical biologic and molecular differences between self-renewing progenitor-like LSCs and hematopoietic stem cells could potentially be targeted by novel therapeutic strategies.
dc.language.isoenen
dc.subjectLeukaemia Stem Cellsen
dc.subjectOncogenesen
dc.subjectMLL Geneen
dc.subjectSelf-Renewalen
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshHematopoietic Stem Cells
dc.subject.meshLeukemia
dc.subject.meshMyeloid-Lymphoid Leukemia Protein
dc.subject.meshNeoplastic Stem Cells
dc.subject.meshOncogene Proteins, Fusion
dc.titleGrist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Leukaemia Biology Group, Paterson Institute for Cancer Research, Manchester, M20 4BX, UK.en
dc.identifier.journalInternational Journal of Hematologyen
html.description.abstractMLL fusion oncogenes are pathogenically associated with 5-10% of human acute leukemias. Through multiple interactions with chromatin regulatory factors, they convert a normal hematopoietic hierarchy into a leukemia cell hierarchy sustained at its apex by a population of inappropriately self-renewing myeloid cells termed leukemia stem cells (LSCs). Initiation of the aberrant leukemia cell hierarchy is associated with an abnormal epigenetic state at Hoxa and Meis1 loci, with concomitant high level Hoxa and Meis1 expression. This introduces at the level of the myeloblast, or thereabouts, a finite probability of self-renewal division where none previously existed. In contrast, differentiation-mediated exit of LSCs from the self-renewing compartment of the leukemia clone depends on the prevailing levels of the transcription factor Myb, which functions as part of an LSC maintenance program influenced, but not directly controlled, by Hoxa and Meis1. Critical biologic and molecular differences between self-renewing progenitor-like LSCs and hematopoietic stem cells could potentially be targeted by novel therapeutic strategies.


This item appears in the following Collection(s)

Show simple item record